{
  "$schema": "folio-library-document/v1",
  "id": "10665-69653",
  "title": "Phase préparatoire à l' instauration de la vaccination anti-papillomavirus : directives stratégiques à l' intention des pays",
  "variant": "pdf",
  "pages": 30,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "Introduction",
      "number": null,
      "page": 6,
      "pageLabel": "1",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-introduction"
    },
    {
      "level": 1,
      "title": "Cancer du col de l’utérus et infection à papillomavirus",
      "number": null,
      "page": 6,
      "pageLabel": "1",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-cancer-du-col-de-lutérus-et-infection-à-papillom"
    },
    {
      "level": 1,
      "title": "Vaccins anti-papillomavirus",
      "number": null,
      "page": 8,
      "pageLabel": "3",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-002-vaccins-anti-papillomavirus"
    },
    {
      "level": 1,
      "title": "Populations visées par la vaccination anti-papillomavirus",
      "number": null,
      "page": 9,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-003-populations-visées-par-la-vaccination-anti-papil"
    },
    {
      "level": 1,
      "title": "Particularités des vaccins anti-papillomavirus",
      "number": null,
      "page": 11,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-004-particularités-des-vaccins-anti-papillomavirus"
    },
    {
      "level": 1,
      "title": "Une possibilité unique",
      "number": null,
      "page": 11,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-005-une-possibilité-unique"
    },
    {
      "level": 1,
      "title": "Un produit coûteux",
      "number": null,
      "page": 14,
      "pageLabel": "9",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-006-un-produit-coûteux"
    },
    {
      "level": 1,
      "title": "Les problèmes que pose l’instauration de la vaccination",
      "number": null,
      "page": 15,
      "pageLabel": "10",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-007-les-problèmes-que-pose-linstauration-de-la-vacci"
    },
    {
      "level": 1,
      "title": "Rompre avec l’habitude",
      "number": null,
      "page": 15,
      "pageLabel": "10",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-008-rompre-avec-lhabitude"
    },
    {
      "level": 1,
      "title": "Sensibilisation, information et communication",
      "number": null,
      "page": 16,
      "pageLabel": "11",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-009-sensibilisation-information-et-communication"
    },
    {
      "level": 1,
      "title": "Mesures à prendre",
      "number": null,
      "page": 17,
      "pageLabel": "12",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-010-mesures-à-prendre"
    },
    {
      "level": 1,
      "title": "Prestation des services",
      "number": null,
      "page": 20,
      "pageLabel": "15",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-011-prestation-des-services"
    },
    {
      "level": 1,
      "title": "Accéder aux populations cibles",
      "number": null,
      "page": 20,
      "pageLabel": "15",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": null
    },
    {
      "level": 1,
      "title": "Les partenariats entre les programmes",
      "number": null,
      "page": 22,
      "pageLabel": "17",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-012-les-partenariats-entre-les-programmes"
    },
    {
      "level": 1,
      "title": "Le suivi et l’évaluation",
      "number": null,
      "page": 22,
      "pageLabel": "17",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-013-le-suivi-et-lévaluation"
    },
    {
      "level": 1,
      "title": "Mesures à prendre",
      "number": null,
      "page": 23,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-014-mesures-à-prendre"
    },
    {
      "level": 1,
      "title": "Gestion d’ensemble et ﬁnancement",
      "number": null,
      "page": 25,
      "pageLabel": "20",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-015-gestion-densemble-et-ﬁnancement"
    },
    {
      "level": 1,
      "title": "Mesures à prendre",
      "number": null,
      "page": 26,
      "pageLabel": "21",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-016-mesures-à-prendre"
    },
    {
      "level": 1,
      "title": "Conclusion",
      "number": null,
      "page": 28,
      "pageLabel": "23",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-017-conclusion"
    },
    {
      "level": 1,
      "title": "Autres sources d’information",
      "number": null,
      "page": 29,
      "pageLabel": "24",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-018-autres-sources-dinformation"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 6,
      "labelStart": "I",
      "labelEnd": "1",
      "words": 788,
      "summary": {
        "text": "The front matter of the French edition of WHO's 2006 guidance on preparing for the introduction of HPV vaccines (WHO/RHR/06.11), with copyright, disclaimers and contents. It notes that the content stems from a March 2006 technical consultation of experts on sexual and reproductive health programmes and HPV vaccines. It lists the participating experts and the UNFPA and WHO departments involved.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "préparatoire instauration",
          "heading": false
        },
        {
          "term": "vaccins anti-papillomavirus",
          "heading": false
        },
        {
          "term": "vaccination anti-papillomavirus",
          "heading": false
        },
        {
          "term": "organisation mondiale",
          "heading": false
        },
        {
          "term": "phase préparatoire",
          "heading": false
        },
        {
          "term": "felicity cutts",
          "heading": false
        },
        {
          "term": "directives stratégiques",
          "heading": false
        },
        {
          "term": "intention des",
          "heading": false
        }
      ],
      "extract": "Phase préparatoire à l’instauration de la vaccination anti-papillomavirus directives stratégiques et programmatiques à l’intention des pays WHO/RHR/06.11 Phase préparatoire à l’instauration de la vaccination anti-papillomavirus : directives stratégiques et programmatiques à l’intention des pays Phase préparatoire à l’instauration de la vaccination anti-papillomavirus : directives stratégiques et programma- tiques à",
      "extractCut": true,
      "blocks": [
        "library/10665-69653/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-introduction",
      "number": null,
      "title": "Introduction",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 132,
      "summary": {
        "text": "Introduces the French edition, explaining that it draws on the UNFPA/WHO consultation held in Montreux in March 2006 and aims to alert stakeholders in sexual and reproductive health, immunization, child and adolescent health and cancer control to key issues in preparing for HPV vaccines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "santé sexuelle",
          "heading": false
        },
        {
          "term": "lutte anticancéreuse",
          "heading": false
        },
        {
          "term": "sur les",
          "heading": false
        },
        {
          "term": "génésique",
          "heading": false
        },
        {
          "term": "les programmes",
          "heading": false
        }
      ],
      "extract": "consultation technique UNFPA/OMS sur les vac- cins anti-papillomavirus et les programmes de santé sexuelle et génésique organisée en mars 2006 à Montreux (Suisse). Elle a pour but d’attirer l’attention des nombreuses parties prenantes aux programmes de santé sexuelle et génésique, de vaccination, de santé de l’enfant et de l’adolescent et de lutte anticancéreuse sur les grandes ques- tions liées à l’utilisation",
      "extractCut": true
    },
    {
      "id": "sec-001-cancer-du-col-de-lutérus-et-infection-à-papillom",
      "number": null,
      "title": "Cancer du col de l’utérus et infection à papillomavirus",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 8,
      "labelStart": "1",
      "labelEnd": "3",
      "words": 947,
      "summary": {
        "text": "Describes cervical cancer as the second most common cancer in women, with about 500 000 new cases and 250 000 deaths yearly, mostly in low-income countries, and nearly all linked to HPV. It explains the natural history of HPV infection, the role of screening in prevention and the potential of visual inspection with acetic acid and cryotherapy in low-resource settings. It also refers to the 2005 World Health Assembly resolution on cancer control and notes that early invasive cancer can be cured by surgery or radiotherapy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "col",
          "heading": true
        },
        {
          "term": "infection papillomavirus",
          "heading": true
        },
        {
          "term": "col utérin",
          "heading": false
        },
        {
          "term": "lésions précancéreuses",
          "heading": false
        },
        {
          "term": "des lésions",
          "heading": false
        },
        {
          "term": "les lésions",
          "heading": false
        },
        {
          "term": "des cancers",
          "heading": false
        },
        {
          "term": "génotypes dits",
          "heading": false
        }
      ],
      "extract": "infection à papillomavirus Le cancer du col utérin est le deuxième cancer de la femme par ordre d’importance dans le monde, avec environ 500 000 nouveaux cas et 250 000 décès par an. Près de 80 % des cas se produisent dans les pays à faible revenu, où il est le cancer le plus fréquent chez la femme. Presque tous les cancers du col (99 %) sont liés à une infection génitale par le papillomavirus humain (HPV), qui est",
      "extractCut": true
    },
    {
      "id": "sec-002-vaccins-anti-papillomavirus",
      "number": null,
      "title": "Vaccins anti-papillomavirus",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 9,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 268,
      "summary": {
        "text": "Explains that HPV vaccines consist of non-infectious virus-like particles and that two prophylactic vaccines were highly effective against persistent infection and cervical lesions. It notes that questions remain on long-term efficacy, need for boosters and use in pregnant women and immunocompromised people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vaccins prophylactiques",
          "heading": false
        },
        {
          "term": "demande homologation",
          "heading": false
        },
        {
          "term": "contre les",
          "heading": false
        },
        {
          "term": "deux vac",
          "heading": false
        },
        {
          "term": "anti-papillomavirus",
          "heading": true
        },
        {
          "term": "efﬁcaces contre",
          "heading": false
        },
        {
          "term": "vac cins",
          "heading": false
        },
        {
          "term": "les types",
          "heading": false
        }
      ],
      "extract": "Les vaccins anti-papillomavirus sont constitués de pseudo-particules virales synthétisées par auto assemblage de protéines L1, L1 étant une protéine majeure de la capside virale. Ces par- ticules ne contenant pas de matériel génétique viral, elles ne peuvent pas se multiplier et ne sont pas infectieuses. Lors d’études de validation du principe, deux vaccins prophylactiques se sont révélés extrêmement efﬁcaces contre",
      "extractCut": true
    },
    {
      "id": "sec-003-populations-visées-par-la-vaccination-anti-papil",
      "number": null,
      "title": "Populations visées par la vaccination anti-papillomavirus",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 11,
      "labelStart": "4",
      "labelEnd": "6",
      "words": 733,
      "summary": {
        "text": "Explains that HPV vaccination should ideally occur before sexual debut, since infection is acquired soon after, and describes the likely licensed age range and expected availability of the two vaccines. It discusses uncertain benefits for males, younger children, people with HIV and pregnant women. It links vaccine introduction to WHO's reproductive health strategy, which calls for using existing services as entry points.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vaccination anti-papillomavirus",
          "heading": true
        },
        {
          "term": "les femmes",
          "heading": false
        },
        {
          "term": "des femmes",
          "heading": false
        },
        {
          "term": "chez les",
          "heading": false
        },
        {
          "term": "santé sexuelle",
          "heading": false
        },
        {
          "term": "les soins",
          "heading": false
        },
        {
          "term": "femmes est",
          "heading": false
        },
        {
          "term": "santé génésique",
          "heading": false
        }
      ],
      "extract": "par la vaccination anti-papillomavirus La principale considération à prendre en compte pour déﬁnir la population à vacciner est que l’infection à papillomavirus se transmet par voie sexuelle et s’acquiert généralement pendant les années qui suivent le début de l’activité sexuelle. Le vaccin doit donc être administré de préférence avant le début de l’activité sexuelle, c’est-à-dire avant tout risque d’exposition au",
      "extractCut": true
    },
    {
      "id": "sec-004-particularités-des-vaccins-anti-papillomavirus",
      "number": null,
      "title": "Particularités des vaccins anti-papillomavirus",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 52,
      "summary": {
        "text": "Notes that HPV vaccines could strengthen links between health services and prevent a common cancer and widespread genital dysplasia and warts on a large scale, and introduces their main features.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "particularités",
          "heading": true
        },
        {
          "term": "vaccins",
          "heading": true
        },
        {
          "term": "anti-papillomavirus",
          "heading": true
        }
      ],
      "extract": "papillomavirus Les vaccins anti-papillomavirus sont de nature à renforcer les interactions entre les différents ser- vices de santé et peuvent permettre de prévenir à très grande échelle un cancer courant et les cas de dysplasie génitale et de condylome acuminé plus fréquents encore. Les particularités essentielles de ces vaccins sont exposées ci-après.",
      "extractCut": false
    },
    {
      "id": "sec-005-une-possibilité-unique",
      "number": null,
      "title": "Une possibilité unique",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 14,
      "labelStart": "6",
      "labelEnd": "9",
      "words": 834,
      "summary": {
        "text": "Explains that HPV vaccines require new delivery approaches, target a different population from usual immunization programmes and involve multiple stakeholders in the sensitive field of sexual health. It describes the Global Immunization Vision and Strategy's plan to extend immunization beyond infants and the priority choices facing cancer control programmes. It presents the vaccines as a chance to encourage delayed sexual debut and condom use through strong partnerships.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vaccins anti-papillomavirus",
          "heading": false
        },
        {
          "term": "les vaccins",
          "heading": false
        },
        {
          "term": "vaccination anti-papil",
          "heading": false
        },
        {
          "term": "anti-papil lomavirus",
          "heading": false
        },
        {
          "term": "des vaccins",
          "heading": false
        },
        {
          "term": "dans les",
          "heading": false
        },
        {
          "term": "tous les",
          "heading": false
        },
        {
          "term": "stratégie mondiale",
          "heading": false
        }
      ],
      "extract": "Les vaccins anti-papillomavirus présentent plu- sieurs caractéristiques qui méritent une attention particulière : leur utilisation requiert de nouvelles formules de prestation des services ; la population cible est différente de celle généralement visée par les programmes nationaux de vaccination ; de multiples acteurs doivent être associés à l’action de sensibilisation et à la communication sociale ; la meilleure",
      "extractCut": true
    },
    {
      "id": "sec-006-un-produit-coûteux",
      "number": null,
      "title": "Un produit coûteux",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 15,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 259,
      "summary": {
        "text": "Notes that HPV vaccines will likely cost much more than traditional EPI vaccines, with international financing such as GAVI under discussion. It warns that private-sector introduction among wealthier groups could deepen health inequalities unless strong public-private partnerships are built.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "les pays",
          "heading": false
        },
        {
          "term": "des vaccins",
          "heading": false
        },
        {
          "term": "pour les",
          "heading": false
        },
        {
          "term": "est probable",
          "heading": false
        },
        {
          "term": "sion",
          "heading": false
        },
        {
          "term": "privé",
          "heading": false
        },
        {
          "term": "sera",
          "heading": false
        },
        {
          "term": "prix",
          "heading": false
        }
      ],
      "extract": "On ignore encore quel sera le prix des vaccins anti- papillomavirus pour les pays en développement, mais il est probable qu’ils coûteront nettement plus cher que les traditionnels vaccins du PEV, du moins au départ, même avec un système de prix différentiel entre pays développés et pays en dével- oppement. Des négociations sont en cours pour bénéﬁcier de l’aide de mécanismes de ﬁnance- ment internationaux (comme",
      "extractCut": true
    },
    {
      "id": "sec-007-les-problèmes-que-pose-linstauration-de-la-vacci",
      "number": null,
      "title": "Les problèmes que pose l’instauration de la vaccination",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 251,
      "summary": {
        "text": "Stresses that HPV vaccine delivery must reflect each country's costs, feasibility and cultural acceptability, as vaccinating young girls against a sexually transmitted infection may be sensitive. It calls for avoiding backlash, giving complementary prevention messages and using the vaccine to build synergy between immunization, cancer control and sexual health programmes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "instauration",
          "heading": true
        },
        {
          "term": "vaccination",
          "heading": true
        },
        {
          "term": "les",
          "heading": true
        },
        {
          "term": "santé sexuelle",
          "heading": false
        },
        {
          "term": "les adolescents",
          "heading": false
        },
        {
          "term": "des services",
          "heading": false
        },
        {
          "term": "col",
          "heading": false
        },
        {
          "term": "anti-papillomavirus",
          "heading": false
        }
      ],
      "extract": "l’instauration de la vaccination La stratégie de prestation des services et de pro- motion des vaccins anti-papillomavirus devra se fonder sur des critères de coût, de faisabilité et d’acceptabilité culturelle propres à chaque pays. Il se peut que la vaccination des jeunes ﬁlles contre le cancer du col et d’autres atteintes génitales dues à des infections sexuellement transmissibles soit une question délicate dans",
      "extractCut": true
    },
    {
      "id": "sec-008-rompre-avec-lhabitude",
      "number": null,
      "title": "Rompre avec l’habitude",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 16,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 359,
      "summary": {
        "text": "Argues that the vaccines' special features require new ways for programmes to work together and with the private sector, and international partnerships to speed access in developing countries. It highlights the need for balanced communication on the vaccines' benefits and limits within a broad cervical cancer prevention strategy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "des difﬁcultés",
          "heading": false
        },
        {
          "term": "sur les",
          "heading": false
        },
        {
          "term": "santé sexuelle",
          "heading": false
        },
        {
          "term": "des vaccins",
          "heading": false
        },
        {
          "term": "les pays",
          "heading": false
        },
        {
          "term": "les programmes",
          "heading": false
        },
        {
          "term": "collaboration entre",
          "heading": false
        },
        {
          "term": "anti-papillomavirus",
          "heading": false
        }
      ],
      "extract": "En raison des caractéristiques particulières des vaccins anti-papillomavirus, il faudra, dans chaque pays, trouver de nouveaux modes de collaboration entre tous les programmes concernés. En outre, comme il est dit plus haut, les programmes publics devront agir de concert avec le secteur privé. Au niveau international, il faut dès à présent créer des partenariats pour tenter de raccourcir le délai habituel entre",
      "extractCut": true
    },
    {
      "id": "sec-009-sensibilisation-information-et-communication",
      "number": null,
      "title": "Sensibilisation, information et communication",
      "level": 1,
      "pageStart": 16,
      "pageEnd": 17,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 557,
      "summary": {
        "text": "Sets out key messages for presenting HPV vaccines, including that HPV causes over 99% of cervical cancers, is very common and highly contagious, and often goes unnoticed. It stresses explaining clearly what the vaccine can and cannot do, alongside lifestyle information given to young people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "les femmes",
          "heading": false
        },
        {
          "term": "des cancers",
          "heading": false
        },
        {
          "term": "vaccins anti-papillomavirus",
          "heading": false
        },
        {
          "term": "voie sexuelle",
          "heading": false
        },
        {
          "term": "sont les",
          "heading": false
        },
        {
          "term": "chez les",
          "heading": false
        },
        {
          "term": "activité sexuelle",
          "heading": false
        },
        {
          "term": "papillomavirus est",
          "heading": false
        }
      ],
      "extract": "et communication L’une des premières questions à se poser est comment présenter les nouveaux vaccins. Etant entendu que chaque pays devra tenir compte du contexte socioculturel et religieux qui lui est pro- pre, les principaux messages sont les suivants : • Le papillomavirus est à l’origine de plus de 99 % des cancers du col utérin et intervient dans d’autres cancers et maladies. • Le papillomavirus est un des virus",
      "extractCut": true
    },
    {
      "id": "sec-010-mesures-à-prendre",
      "number": null,
      "title": "Mesures à prendre",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 20,
      "labelStart": "12",
      "labelEnd": "15",
      "words": 782,
      "summary": {
        "text": "Lists action points on advocacy, information and communication, such as gathering national data on cancer burden, HPV strains and age of sexual debut, and tailoring communication to decision-makers, health workers, women and communities. It also covers materials, training and financing questions such as insurance coverage. It urges using HPV vaccination to strengthen existing programmes for adolescents, including school-based sexual health, nutrition, tobacco and HIV education.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "les prestateurs",
          "heading": false
        },
        {
          "term": "vaccination anti-papillomavirus",
          "heading": false
        },
        {
          "term": "les groupes",
          "heading": false
        },
        {
          "term": "pour les",
          "heading": false
        },
        {
          "term": "les femmes",
          "heading": false
        },
        {
          "term": "exemple les",
          "heading": false
        },
        {
          "term": "les organisations",
          "heading": false
        },
        {
          "term": "anti-papillomavirus est",
          "heading": false
        }
      ],
      "extract": "En matière de sensibilisation, d’information et de communication, les impératifs sont les suivants : • L’interaction entre les responsables de l’action de sensibilisation, de la prestation des services et de la gestion d’ensemble compte beaucoup, notamment pour rassembler les données sci- entiﬁques et les informations sur la situation dans le pays (par exemple charge du cancer du col utérin, souches de HPV circulant",
      "extractCut": true
    },
    {
      "id": "sec-011-prestation-des-services",
      "number": null,
      "title": "Prestation des services",
      "level": 1,
      "pageStart": 20,
      "pageEnd": 22,
      "labelStart": "15",
      "labelEnd": "17",
      "words": 1092,
      "summary": {
        "text": "Discusses, in French, delivering HPV vaccination to target groups, noting that licensing will probably cover ages 9–26, split into a main group of girls aged 9–13, to be reached before sexual activity begins, and a catch-up group. It considers delivery through schools, adolescent services and other contact points and the challenges of each. It urges that HPV vaccination be offered within comprehensive, rights-based services rather than as a stand-alone strategy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prestation des",
          "heading": true
        },
        {
          "term": "des services",
          "heading": true
        },
        {
          "term": "les ﬁlles",
          "heading": false
        },
        {
          "term": "vacciner les",
          "heading": false
        },
        {
          "term": "vaccination anti-papillomavirus",
          "heading": false
        },
        {
          "term": "les jeunes",
          "heading": false
        },
        {
          "term": "les femmes",
          "heading": false
        },
        {
          "term": "vaccin anti-papillomavirus",
          "heading": false
        }
      ],
      "extract": "cibles L’autorisation de mise sur le marché des vac- cins déﬁnira probablement la tranche d’âge 9-26 ans comme population cible. Cette tranche d’âge devrait être divisée en deux catégories : le groupe principal et le groupe de « rattrapage ». La population cible principale Il s’agira très probablement des ﬁlles de 9 à 13 ans, le but étant de les vacciner avant le début de l’activité sexuelle. Chaque pays devra",
      "extractCut": true
    },
    {
      "id": "sec-012-les-partenariats-entre-les-programmes",
      "number": null,
      "title": "Les partenariats entre les programmes",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 203,
      "summary": {
        "text": "Advises, in French, that HPV vaccination programmes build on existing structures such as the vaccine cold chain to be cost-effective, and use partnerships with programmes and providers already in contact with target groups and women.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "les",
          "heading": true
        },
        {
          "term": "vaccination anti-papillomavirus",
          "heading": false
        },
        {
          "term": "les services",
          "heading": false
        },
        {
          "term": "avec les",
          "heading": false
        },
        {
          "term": "partenariats",
          "heading": true
        },
        {
          "term": "des",
          "heading": false
        },
        {
          "term": "programmes",
          "heading": true
        },
        {
          "term": "devra",
          "heading": false
        }
      ],
      "extract": "programmes Il faudra planiﬁer et organiser le programme de façon à utiliser le plus rentablement possible les services existants ou de les renforcer si néces- saire. La vaccination anti-papillomavirus doit s’appuyer sur les structures déjà en place au niveau national telles que les infrastructures de la chaîne du froid pour la conservation des vaccins. De cette façon, l’efﬁcacité sera maximale par rap- port au coût",
      "extractCut": true
    },
    {
      "id": "sec-013-le-suivi-et-lévaluation",
      "number": null,
      "title": "Le suivi et l’évaluation",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 390,
      "summary": {
        "text": "Explains, in French, the need to plan monitoring and evaluation of HPV vaccination from the outset, using routine immunization surveillance for process indicators. It notes that effects on genital warts and precancerous lesions will appear before effects on cancer, and that reporting of adverse events, including by the private sector, will be important.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sur les",
          "heading": false
        },
        {
          "term": "surveil lance",
          "heading": false
        },
        {
          "term": "fréquence des",
          "heading": false
        },
        {
          "term": "effet sur",
          "heading": false
        },
        {
          "term": "des manifestations",
          "heading": false
        },
        {
          "term": "les résultats",
          "heading": false
        },
        {
          "term": "les données",
          "heading": false
        },
        {
          "term": "suivi",
          "heading": true
        }
      ],
      "extract": "Même si la mise en place d’un système efﬁcace de suivi et d’évaluation est une activité « d’aval », il est important d’étudier dès le stade préparatoire comment évaluer le processus et les résultats. Les indicateurs de processus devront être mesu- rés dans le cadre de la surveillance systématique des programmes nationaux de vaccination. Il est probable qu’on observera d’abord un effet sur la fréquence des condylomes",
      "extractCut": true
    },
    {
      "id": "sec-014-mesures-à-prendre",
      "number": null,
      "title": "Mesures à prendre",
      "level": 1,
      "pageStart": 23,
      "pageEnd": 25,
      "labelStart": "18",
      "labelEnd": "20",
      "words": 430,
      "summary": {
        "text": "Lists, in French, the actions national programmes should take on service delivery, such as linking the many actors involved, defining the main target group, tackling sociocultural barriers to vaccinating young adolescents, assessing school enrolment and setting process and outcome indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "concevoir des",
          "heading": false
        },
        {
          "term": "vaccination anti-papillomavirus",
          "heading": false
        },
        {
          "term": "santé sexuelle",
          "heading": false
        },
        {
          "term": "sur les",
          "heading": false
        },
        {
          "term": "génésique destinés",
          "heading": false
        },
        {
          "term": "des programmes",
          "heading": false
        },
        {
          "term": "les agents",
          "heading": false
        },
        {
          "term": "des messages",
          "heading": false
        }
      ],
      "extract": "Les programmes nationaux devront prendre les mesures suivantes : • Créer des liens entre les nombreux acteurs qui interviennent dans la mise en oeuvre. • Déﬁnir la population cible principale en fonction des points d’accès les plus pratiques et de l’âge le plus précoce auquel commence l’activité sex- uelle. • S’attaquer aux facteurs socioculturels qui font obstacle à la vaccination des jeunes adoles- cents. •",
      "extractCut": true
    },
    {
      "id": "sec-015-gestion-densemble-et-ﬁnancement",
      "number": null,
      "title": "Gestion d’ensemble et ﬁnancement",
      "level": 1,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 927,
      "summary": {
        "text": "Discusses, in French, overall management and financing of HPV vaccination, calling for resources from international sources and national health budgets within a broad strategy to strengthen health systems. It covers the high cost of the vaccines, the need for affordable prices and international funding commitments. It also addresses regulatory tasks after licensing, such as private-sector adverse event reporting, post-marketing surveillance and package inserts.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ﬁnancement",
          "heading": true
        },
        {
          "term": "vaccins anti-papillomavirus",
          "heading": false
        },
        {
          "term": "vaccination anti-papillomavirus",
          "heading": false
        },
        {
          "term": "des vaccins",
          "heading": false
        },
        {
          "term": "pour les",
          "heading": false
        },
        {
          "term": "les pouvoirs",
          "heading": false
        },
        {
          "term": "des fonds",
          "heading": false
        },
        {
          "term": "des pays",
          "heading": false
        }
      ],
      "extract": "sources pour renforcer le système de santé et acheter les vaccins anti-papillomavirus, tant au niveau international que dans le cadre des budgets nationaux de la santé. L’instauration de la vaccina- tion anti-papillomavirus devrait être ﬁnancée dans le cadre d’une stratégie globale faisant intervenir plusieurs partenaires, au niveau mondial et au sein même des pays, et d’une augmentation générale des ressources",
      "extractCut": true
    },
    {
      "id": "sec-016-mesures-à-prendre",
      "number": null,
      "title": "Mesures à prendre",
      "level": 1,
      "pageStart": 26,
      "pageEnd": 28,
      "labelStart": "21",
      "labelEnd": "23",
      "words": 442,
      "summary": {
        "text": "Lists, in French, the management and financing actions needed, starting with a national working group to coordinate health programmes, civil society and the private sector in drafting an HPV vaccination strategy. It also calls for more information on some issues and for full guidelines and protocols on giving the vaccines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vaccination anti-papillomavirus",
          "heading": false
        },
        {
          "term": "des fonds",
          "heading": false
        },
        {
          "term": "des programmes",
          "heading": false
        },
        {
          "term": "vac cination",
          "heading": false
        },
        {
          "term": "pour prévoir",
          "heading": false
        },
        {
          "term": "les pays",
          "heading": false
        },
        {
          "term": "des services",
          "heading": false
        },
        {
          "term": "santé sexuelle",
          "heading": false
        }
      ],
      "extract": "Pour ce qui a trait à la gestion d’ensemble et au ﬁnancement, il conviendra de prendre les mesures suivantes : • La stratégie qui permettra d’instaurer des services complets et efﬁcaces de vaccination anti-papillomavirus doit être élaborée en col- laboration avec un vaste ensemble d’acteurs. Chaque pays devra constituer un groupe de travail national pour créer des mécanismes de coordination entre les programmes de",
      "extractCut": true
    },
    {
      "id": "sec-017-conclusion",
      "number": null,
      "title": "Conclusion",
      "level": 1,
      "pageStart": 28,
      "pageEnd": 29,
      "labelStart": "23",
      "labelEnd": "24",
      "words": 245,
      "summary": {
        "text": "Concludes, in French, that HPV vaccination meets an important public health need as part of comprehensive cervical cancer control, that universal access to prevention, screening and treatment is crucial and that equity questions must be addressed. It ends with a note on the conditions for which the quadrivalent vaccine was licensed by the US FDA.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "néoplasie intra-épithéliale",
          "heading": false
        },
        {
          "term": "col utérin",
          "heading": false
        },
        {
          "term": "accès universel",
          "heading": false
        },
        {
          "term": "papillomavirus humain",
          "heading": false
        },
        {
          "term": "les femmes",
          "heading": false
        },
        {
          "term": "universel aux",
          "heading": false
        },
        {
          "term": "grades",
          "heading": false
        },
        {
          "term": "fda",
          "heading": false
        }
      ],
      "extract": "La vaccination anti-papillomavirus répond à un besoin de santé publique important et s’inscrit dans une stratégie globale de lutte contre le cancer du col de l’utérus. L’accès universel aux services de prévention, de dépistage et de traitement du cancer du col sera crucial pour réduire la charge de ce cancer dans le monde. L’utilisation de ces nouveaux vaccins soulève d’importantes questions d’équité qu’il faut",
      "extractCut": true
    },
    {
      "id": "sec-018-autres-sources-dinformation",
      "number": null,
      "title": "Autres sources d’information",
      "level": 1,
      "pageStart": 29,
      "pageEnd": 30,
      "labelStart": "24",
      "labelEnd": "Sec2:25",
      "words": 119,
      "summary": {
        "text": "Lists, in French, further sources of information, with websites of UNFPA, WHO, the Global Immunization Vision and Strategy and the GAVI Alliance, and the WHO departments to contact.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "recherche génésiques",
          "heading": false
        },
        {
          "term": "santé",
          "heading": false
        },
        {
          "term": "ethique",
          "heading": false
        },
        {
          "term": "reproductive-health",
          "heading": false
        }
      ],
      "extract": "UNFPA http://www.unfpa.org/sitemap/sitemap-fra.htm OMS http://www.who.int/fr/index.html http://www.who.int/reproductive-health/fr/index.htm http://www.who.int/cancer/en/ http://www.who.int/reproductive-health/pages_resources/listing_cancer.en.html GIVS http://www.who.int/immunization/givs/en/index.html Alliance mondiale pour les vaccins et la vaccination http://www.gavialliance.org/ Pour plus d’informations,",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 27,
      "items": [
        "p3: pdf-labels III, printed ii",
        "p4: pdf-labels IV, printed iii",
        "p5: pdf-labels Sec1:4, printed iv",
        "p6: pdf-labels Sec2:1, printed 1, contents 1",
        "p7: pdf-labels Sec2:2, printed 2",
        "p8: pdf-labels Sec2:3, printed 3, contents 3",
        "p9: pdf-labels Sec2:4, printed 4, contents 4",
        "p10: pdf-labels Sec2:5, printed 5",
        "p11: pdf-labels Sec2:6, printed 6, contents 6",
        "p12: pdf-labels Sec2:7, printed 7",
        "p13: pdf-labels Sec2:8, printed 8",
        "p14: pdf-labels Sec2:9, printed 9, contents 9",
        "p15: pdf-labels Sec2:10, printed 10, contents 10",
        "p16: pdf-labels Sec2:11, printed 11, contents 11",
        "p17: pdf-labels Sec2:12, printed 12, contents 12",
        "p18: pdf-labels Sec2:13, printed 13",
        "p19: pdf-labels Sec2:14, printed 14",
        "p20: pdf-labels Sec2:15, printed 15, contents 15",
        "p21: pdf-labels Sec2:16, printed 16",
        "p22: pdf-labels Sec2:17, printed 17, contents 17",
        "p23: pdf-labels Sec2:18, printed 18, contents 18",
        "p24: pdf-labels Sec2:19, printed 19",
        "p25: pdf-labels Sec2:20, printed 20, contents 20",
        "p26: pdf-labels Sec2:21, printed 21, contents 21",
        "p27: pdf-labels Sec2:22, printed 22",
        "p28: pdf-labels Sec2:23, printed 23, contents 23",
        "p29: pdf-labels Sec2:24, printed 24, contents 24"
      ]
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "santé des",
      "heading": false
    },
    {
      "term": "les vaccins",
      "heading": false
    },
    {
      "term": "pour les",
      "heading": false
    },
    {
      "term": "vaccination anti-papillomavirus",
      "heading": true
    },
    {
      "term": "sur les",
      "heading": false
    },
    {
      "term": "dans les",
      "heading": false
    },
    {
      "term": "les femmes",
      "heading": true
    },
    {
      "term": "les pays",
      "heading": false
    },
    {
      "term": "par les",
      "heading": true
    },
    {
      "term": "contre les",
      "heading": false
    },
    {
      "term": "sont les",
      "heading": false
    },
    {
      "term": "anti-papillomavirus est",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "I",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "II",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "ii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "iii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 8,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 13,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 14,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "12",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "13",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 19,
      "label": "14",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 20,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "16",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 22,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "19",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 25,
      "label": "20",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "22",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 28,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "24",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "Sec2:25",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1",
      "title": "Prévalence de l’infection à papillomavirus, des lésions précancéreuses et du cancer du col de l’utérus chez la femme, par âge",
      "page": 7,
      "pageLabel": "2",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2",
      "title": "Prévalence (en %) des différents types de papillomavirus chez les femmes cancéreuses, par région",
      "page": 9,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 20,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 20,
      "note": "one level"
    },
    {
      "kind": "figures",
      "state": "partial",
      "count": 0,
      "note": "2 captioned in the text, none kept"
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 20,
      "note": "20 of 20 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-69653"
  }
}
